Thanks to these seminal results, the TCR transfer clinical application was widened to other relevant targets, such as the New York esophageal squamous cell carcinoma (NY-ESO)-1, expressed in Melanoma and Synovial Sarcoma (30, 43) and the carcinoembryonic antigen (CEA), expressed in colorectal cancer (31). This evidence concerns the gene CEACAM5 and colorectal cancer.